In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia

Research output: Contribution to journalArticle

Bibtex

@article{4799634c30274b5ebdbf6d9e16f4142f,
title = "In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia",
abstract = "Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. There was a significant correlation between MRD day 29 and in vitro sensitivity to prednisolone (p < 0.001) and doxorubicin (p = 0.01 7), drugs administered during induction therapy. In patients with t(12;21) (n = 20), in vitro sensitivity to doxorubicin was an independent factor for MRD <0.1{\%} (p = 0.031; R-2 = 0.66). Thus, data show that in vitro drug sensitivity at diagnosis is correlated to cell kill during induction therapy as measured by MRD day 29. (C) 2008 Elsevier Ltd. All rights reserved.",
keywords = "Doxorubicin, Prednisolone, 21), t(12, MRD, In vitro drug resistance, Acute lymphoblastic leukemia, Childhood",
author = "Gudmar Lonnerholm and Ingrid Thorn and Christer Sundstrom and Britt-Marie Frost and Jonas Abrahamsson and Mikael Behrendtz and Jesper Heldrup and Stefan Jacobsson and AiHong Li and Tor Olofsson and Anna Porwit and Stefan Soderhall and Rolf Larsson and Erik Forestier",
year = "2009",
doi = "10.1016/j.leukres.2008.06.012",
language = "English",
volume = "33",
pages = "46--53",
journal = "Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis",
issn = "1873-5835",
publisher = "Elsevier",
number = "1",

}